ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: FDA OKs New Treatment for Soft-Tissue Sarcoma Patients

(This story has been posted on The Wall Street Journal Online's Health Blog at By Jennifer Corbett Dooren Patients with soft-tissue sarcoma, a rare cancer that starts in the body's muscle or connective tissues, now have a new treatment option. The FDA late yesterday approved GlaxoSmithKline's drug Votrient for use in patients with soft-tissue sarcoma, Dow Jones Newswires reports. This is the first new treatment in decades for the cancer. The National Cancer Institute estimates 11,000 cases of soft tissue sarcoma are diagnosed each year in the U.S. Votrient, a tablet taken orally, is already on the U.S. market to treat advanced kidney cancer. It was approved to treat several subtypes of advanced soft-tissue sarcoma, after prior chemotherapy. Votrient's approval follows the March recommendation of an agency advisory panel that the drug's benefits outweighed its risks. Clinical data involving 369 patients showed the drug temporarily slowed tumor growth but it isn't clear if the drug prolongs lives. And the FDA notes that Votrient carries the agency's toughest warning on its label, telling patients and doctors about the potentially fatal liver damage. Patients should be monitored for liver function and treatment halt if liver function declines, the agency says. Separately Thursday, the FDA granted wider approval to Novartis's Afinitor to treat non-cancerous kidney tumors that don't require immediate surgery. Afinitor was first approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs fail. Afinitor was approved to treat kidney tumors that are caused by a rare genetic disease called tuberous sclerosis complex, or TSC, which affects about 40,000 Americans. -For continuously updated news from The Wall Street Journal, see at

Stock News for Novartis (NVS)
10/21/201608:14:00Novartis AG 3Q 2016 - Forecast
10/05/201608:20:00Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
10/02/201623:40:00Novo Nordisk Bets on Riskier Insulin Research
09/23/201613:11:00Novartis receives three new FDA approvals for the expanded use...
08/30/201618:50:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30/201618:31:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/22/201608:50:00Eli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/15/201610:20:00Stada Arzneimittel Braced for Investor Battle
08/05/201614:50:00AbbVie Sues Amgen Over Humira
07/27/201617:10:00Amgen Profit Rises 13%, 2016 Outlook Raised
07/26/201608:00:00Eli Lilly Revenue Rise Helped by New Products
07/25/201616:10:00Stada Arzneimittel Feels More Heat From Active Ownership
07/21/201612:50:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/20/201603:05:00Business Watch -- WSJ
07/19/201619:00:00ADRs End Lower; Ericsson Falls
07/19/201604:36:00Novartis Warns on Profit as It Boosts Investment in Heart-Failure...
07/19/201603:40:00Novartis Warns on Profit as Entresto Investment Weighs
07/19/201602:25:00Novartis Warns Profit Could Fall This Year Due to Increased Spending...
07/15/201611:01:00Novartis AG 2Q 2016 - Forecast
07/12/201619:20:00Amgen Biosimilar Gets Thumbs-Up From FDA Panel

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations